Skip to main content

FORTIS HEALTHCARE LTD ( Slow Motion Multibagger Stock) ( Cmp:177)

Fortis Healthcare (FORHEALT) is into healthcare services. It currently has a network of 11 hospitals primarily in North India and 16 satellite and heart command centers, including one heart command center in Afghanistan. These hospitals include multi-specialty hospitals as well as super-specialty centers providing tertiary and quaternary healthcare to patients in areas such as cardiac care, orthopedics, neurosciences, oncology, renal care, gastroenterology and mother and child care. Established in 1996, Fortis Healthcare is one of the largest private healthcare companies in India promoted by Ranbaxy Laboratories. 


Based in Delhi, FORHEALT is engaged in providing the latest in internationally recognized medical care to patients. It has built a tele-medicine network which connects each of its facilities in order to provide expert care to each patient. It also provides services covering ICU management, ER management, OPD management, radiology and pathology reporting. To boost its business, the company acquired Escorts Heart Institute and Research Center in September 2005. 

 Recent Developments 

12-MAY-15 

Fortis Healthcare, one the leading chain of Hospitals in India Fortis Healthcare announced that Fortis Healthcare International, a step down subsidiary of the company, confirmed that it has received the sum of SGD 111 million from the sale of its Singapore based RadLink-Asia and its subsidiaries to Fullerton Healthcare Group 

 Buy As A Long Term Investment Stock Move Like Apollo Hospital

Comments

  1. Ratul22 September 2015 at 00:24

    Dear ValueBuy, your suggestions and recommendations are really very good. I really appreciate your help to fellow investors.

    ReplyDelete

Post a Comment

Popular posts from this blog

Best Buy For Monday Upper Circuit Expected TCI FINANCE

*Intraday & Short Term News For Monday* *Fii And Dii News*   *TCI FINANCE LTD (501242 & NSE) (31)*   Incorporated in 1973, TCI Finance Ltd (TCIFL) is a Non-Banking Finance Company (NBFC) registered with the RBI and engaged in the business of Inter-Corporate Deposits, investment in equities of bodies corporate etc.   The Company was promoted by Mr. Mahendra Agarwal, who is also the Managing Director and CEO of Gati Ltd, a pioneer in express distribution and supply chain and promoted by TCFIL   The Rs.2 paid-up share of Gati Ltd currently trades at Rs.113. TCIFL has one subsidiary - ITAG Business Solutions Ltd engaged in the business of Knowledge Process Outsourcing (KPO) in the domain of Intellectual Property Services.   *It is co-promoter of GATI LTD. Company is holding 55,12,455 shares (5.09%) stake in GATI LTD. At CMP value of investments is around Rs.62.3crore. Equity is Rs.12.87crore. Thus value of investment works out to Rs.48.4 per share ...
1 comment
Read more

Danlaw Technologies India Ltd: For multi-bagger gains (BSE Code: 532329) (CMP: Rs. 60.75) (FV: Rs.10)

The earnings season so far has been weak and worries over domestic growth continue to weigh on the market sentiment which has led the markets back on the downward path.. A value investor, however, need not worry about the broad markets as value stocks perform better and post good results. One such value-pick is Danlaw Technologies India Ltd. (DTIL). Company background: DTIL is the offshore technology and product development center of its parent company - Danlaw Incorporated, founded by Mr. Raju Dandu and Mr. Lloyd Lawrence in Michigan, USA in 1984. DTIL’s mission is to provide high quality services and products in Automotive Electronics, develop R&D driven Signal Processing technologies for communication and control, configure solutions and provide exceptional Information Technology (IT) services in the areas of education, health, banking and e-governance and provide world-class products and solutions for secured access through biometric access control technologies with intellige...
1 comment
Read more

Some Opportunities Are left in Pharma Sector

Torrent Pharmaceuticals  reported impressive 75% growth in revenues and profit in the first quarter of FY 2016. The sterling performance was driven by the launch of new product in the US market, which has limited competition at present. The focus is on the therapeutic segments of cardiovascular and CNS. There is presence in gastro-intestinal, diabetology, anti-infective, pain management, nephrology, oncology, gynecology and pediatric segments as well. The manufacturing plants for formulations and bulk drugs have been approved by authorities of several regulated and semi-regulated markets such as the US, the UK, Brazil, Germany, Australia and South Africa. Capacity will increase almost 100% once the new plant at Dahej in Gujarat becomes operational. The plant will be one of the largest pharmaceuticals manufacturing facilities in the country at a single location. The unit will primarily cater to the key regulated markets of the US and Europe. Approval from regulators such...
Post a Comment
Read more